Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel
antibiotics, is pleased to announce that at the General Meeting held earlier today all
resolutions as set out in the Notice of General Meeting annexed to the circular to
shareholders dated 23 June 2015 were duly passed. The passing of the resolutions
represents the satisfaction of the first of the two conditions to completion of the conditional
placing of 44,000,000 ordinary shares announced by the Company on 23 June 2015.
The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied.
Enquiries:
Motif Bio plc
Graham Lumsden (Chief Executive Officer)
Robert Bertoldi (Chief Financial Officer)
www.motifbio.com
info@motifbio.com
Zeus Capital Limited (NOMINATED ADVISER & JOINT BROKER)
Phil Walker/John Treacy/Dominic Wilson
+44 (0) 207 183 5860
Northland Capital Partners Limited (JOINT BROKER) +44 (0) 20 7382 1100
Gerry Beaney/David Hignell
John Howes/Mark Treharne (Broking)
Plumtree Capital Limited (FINANCIAL ADVISER) +44 (0) 207 183 2493
Stephen Austin
Yellow Jersey PR Limited (FINANCIAL PR)
Dominic Barretto/Philip Ranger/Fiona Walker
MC Services (TRADE PR)
Raimund Gabriel
Shaun Brown
+44 (0) 7768 537 739
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
Help employers find you! Check out all the jobs and post your resume.
The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied.
Enquiries:
Motif Bio plc
Graham Lumsden (Chief Executive Officer)
Robert Bertoldi (Chief Financial Officer)
www.motifbio.com
info@motifbio.com
Zeus Capital Limited (NOMINATED ADVISER & JOINT BROKER)
Phil Walker/John Treacy/Dominic Wilson
+44 (0) 207 183 5860
Northland Capital Partners Limited (JOINT BROKER) +44 (0) 20 7382 1100
Gerry Beaney/David Hignell
John Howes/Mark Treharne (Broking)
Plumtree Capital Limited (FINANCIAL ADVISER) +44 (0) 207 183 2493
Stephen Austin
Yellow Jersey PR Limited (FINANCIAL PR)
Dominic Barretto/Philip Ranger/Fiona Walker
MC Services (TRADE PR)
Raimund Gabriel
Shaun Brown
+44 (0) 7768 537 739
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
Help employers find you! Check out all the jobs and post your resume.
